Isis files S3. Excerpts:
The net proceeds to be received by the Company from the sale of the
4,000,000 shares of Common Stock being offered hereby are estimated to be
$50,900,000 assuming a public offering price of $12.75 per share and after
deducting estimated offering expenses.
The Company intends to use the net proceeds of this offering for its
research, drug discovery and development programs and for other general
corporate purposes. Expenses to be funded with the offering proceeds include
costs of preclinical and clinical studies, the production of compounds for such
studies and capital expenditures.
The Common Stock is being offered to a limited number of investors
directly by the Company. The price of the Common Stock offered hereby will be
determined through negotiations between the Company and the purchasers.
Common Stock outstanding
after the offering = 31,147,000 shares(1)
1) Based on shares outstanding as of January 31, 1999. Does not
include 7,606,730 shares of Common Stock issuable upon exercise of outstanding
options or 1,248,001 shares of Common Stock issuable upon exercise of
outstanding warrants as of January 31, 1999.
freeedgar.com |
